Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Gastroenterol Nutr ; 59(3): 324-6, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24918980

RESUMO

OBJECTIVES: We sought to characterize emergency department (ED) encounters for pediatric inflammatory bowel disease (IBD) to identify areas for prevention. METHODS: Retrospective chart review of 5 consecutive ED encounters at 7 centers was performed. RESULTS: Of 35 unique encounters by 32 patients, 3 main factors contributed to ED utilization: disease severity or course, day or time of care, and physician instruction. Of the ED encounters, approximately one-fifth were judged medically unnecessary, and one-half avoidable in a more optimal health care system. CONCLUSIONS: ED visits by pediatric patients with IBD may be reduced in a more optimal health care system.


Assuntos
Atenção à Saúde/normas , Serviço Hospitalar de Emergência/estatística & dados numéricos , Mau Uso de Serviços de Saúde/estatística & dados numéricos , Doenças Inflamatórias Intestinais/terapia , Melhoria de Qualidade , Plantão Médico , Progressão da Doença , Humanos , Estudos Retrospectivos , Índice de Gravidade de Doença , Fatores de Tempo
2.
Clin Pediatr (Phila) ; 49(9): 852-65, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20522615

RESUMO

In an 8-week, multicenter, randomized, double-blind study, we evaluated the efficacy and tolerability of pantoprazole (0.3mg/kg [low dose (LD)], 0.6 mg/kg [medium dose (MD)], and 1.2 mg/kg [high dose (HD)]) for delayed-release oral suspension (granules) in patients 1 to 5 years with documented symptoms of gastroesophageal reflux disease (GERD) and endoscopic evidence of reflux-related erosive esophagitis (EE) or histologic esophagitis (HE) consistent with GERD. Patients with HE were randomly assigned to LD, MD, or HD, and patients with EE, to MD or HD. A daily eDiary captured 5 individual GERD symptoms. A total of 60 patients (56 HE, 4 EE) were randomized. Mean weekly GERD symptom score (WGSS, sum of weekly mean frequency scores for 5 individual GERD symptoms) for the modified intention-to-treat HE population at the final week was improved with LD ( P < .001), MD (P = .063), and HD (P < 0.001) (paired t-tests). Patients with EE were healed at week 8. Adverse event incidences did not increase with dose.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico , Esofagite Péptica/tratamento farmacológico , Refluxo Gastroesofágico/tratamento farmacológico , Inibidores da Bomba de Prótons/uso terapêutico , 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem , 2-Piridinilmetilsulfinilbenzimidazóis/efeitos adversos , Biópsia , Canadá , Criança , Pré-Escolar , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/efeitos adversos , Preparações de Ação Retardada/uso terapêutico , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esofagite Péptica/patologia , Esofagoscopia , Feminino , Humanos , Lactente , Masculino , Prontuários Médicos , Pantoprazol , Inibidores da Bomba de Prótons/administração & dosagem , Inibidores da Bomba de Prótons/efeitos adversos , Inquéritos e Questionários , Resultado do Tratamento , Estados Unidos
3.
Clin Pediatr (Phila) ; 45(8): 741-9, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16968960

RESUMO

An age-appropriate questionnaire (GASP-Q) was used to assess the frequency and severity of the gastroesophageal reflux disease (GERD) symptoms: abdominal/belly pain, chest pain/heartburn, pain after eating, nausea, burping/belching, vomiting/regurgitation, choking when eating, and difficulty swallowing, in adolescents age 12 to 16 years. The primary objective was to compare the mean composite symptom score (CSS) at week 8 with baseline after treatment with 20 or 40 mg of pantoprazole. Statistically significant (p < 0.001) improvement in CSS occurred in both groups. Safety was comparable between the 2 groups. Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents.


Assuntos
2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico , Antiulcerosos/uso terapêutico , Refluxo Gastroesofágico/tratamento farmacológico , 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem , Adolescente , Hidróxido de Alumínio , Antiácidos , Antiulcerosos/administração & dosagem , Criança , Método Duplo-Cego , Combinação de Medicamentos , Feminino , Humanos , Hidróxido de Magnésio , Masculino , Pantoprazol , Simeticone , Inquéritos e Questionários
4.
J Pediatr Gastroenterol Nutr ; 42(4): 384-91, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16641576

RESUMO

OBJECTIVE: To evaluate symptom improvement in 53 children (aged 5-11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated with pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms in Pediatrics Questionnaire. METHODS: The GERD Assessment of Symptoms in Pediatrics Questionnaire was used to measure the frequency and severity over the previous 7 days of abdominal/belly pain, chest pain/heartburn, difficulty swallowing, nausea, vomiting/regurgitation, burping/belching, choking when eating and pain after eating. Individual symptom scores were based on the product of the frequency and usual severity of each symptom. The sum of the individual symptom score values made up the composite symptom score (CSS). The primary end point was the change in the mean CSS from baseline to week 8. RESULTS: Mean frequency and severity of each symptom significantly decreased (from P < 0.006 to P < 0.001) over time. Similar significant decreases in CSS at week 8 versus baseline (P < 0.001) were seen in all groups. Significant decreases from baseline in CSS were noted from weeks 1 to 8 in the 20-mg (P < 0.003) and 40-mg (P < 0.001) groups. The 20- and 40-mg doses were significantly (P < 0.05) more effective than the 10-mg dose in improving GERD symptoms at week 1. Adverse events were similar among the treatment groups. CONCLUSIONS: Pantoprazole (20 and 40 mg) is effective in reducing endoscopically proven GERD symptoms in children. Both 20 and 40 mg pantoprazole significantly reduced symptoms as early as 1 week.


Assuntos
Antiulcerosos/uso terapêutico , Benzimidazóis/uso terapêutico , Refluxo Gastroesofágico/tratamento farmacológico , Refluxo Gastroesofágico/patologia , Omeprazol/análogos & derivados , Sulfóxidos/uso terapêutico , 2-Piridinilmetilsulfinilbenzimidazóis , Antiulcerosos/efeitos adversos , Benzimidazóis/efeitos adversos , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Masculino , Omeprazol/efeitos adversos , Omeprazol/uso terapêutico , Pantoprazol , Índice de Gravidade de Doença , Sulfóxidos/efeitos adversos , Inquéritos e Questionários , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...